Novartis Whistleblower Lawsuit Advances Toward Trial

A False Claims Act suit alleges Novartis paid kickbacks to doctors to boost prescriptions of its MS drug Gilenya.

Mar. 31, 2026 at 3:04pm

Got story updates? Submit your updates here. ›

A photorealistic studio still-life featuring a stack of medical pill bottles, a syringe, and a stethoscope arranged elegantly on a clean, white background, conceptually representing issues of healthcare costs and pharmaceutical pricing.A whistleblower lawsuit alleges a major pharmaceutical company used improper financial incentives to drive up drug sales, exposing concerns about rising healthcare costs.NYC Today

A whistleblower can move forward with a False Claims Act lawsuit against Novartis Pharmaceutical Corp. The suit alleges Novartis paid kickbacks to physicians to increase prescriptions of Gilenya, a drug used to treat multiple sclerosis. A New York federal district court judge ruled the whistleblower, Steven Camburn, adequately alleged Novartis knowingly submitted kickback-tainted claims to Medicare, including claims that Novartis paid doctors for speaking at events with no legitimate attendees.

Why it matters

This case highlights ongoing concerns about pharmaceutical companies potentially using kickbacks and other improper incentives to drive up drug sales, which can lead to higher costs for government healthcare programs like Medicare. The False Claims Act allows whistleblowers to sue on behalf of the government and receive a portion of any recovered funds.

The details

The lawsuit alleges Novartis paid physicians to speak at events that had no real attendees, in order to boost prescriptions of Gilenya. The judge ruled the whistleblower, Steven Camburn, adequately alleged Novartis knowingly submitted kickback-tainted claims to Medicare. The case will now move forward to discovery, pretrial motions, and a potential trial.

  • The lawsuit was filed in 2026.

The players

Steven Camburn

The whistleblower who filed the False Claims Act lawsuit against Novartis.

Novartis Pharmaceutical Corp.

A major pharmaceutical company accused of paying kickbacks to physicians to increase prescriptions of its multiple sclerosis drug Gilenya.

Judge Kimba M. Wood

The US District Court judge for the Southern District of New York who ruled the whistleblower's lawsuit can move forward.

Got photos? Submit your photos here. ›

What’s next

The parties must now work on a proposed schedule for discovery, pretrial motions, and trial.

The takeaway

This whistleblower lawsuit underscores the importance of oversight and accountability in the pharmaceutical industry to prevent improper financial incentives that can inflate drug prices and burden government healthcare programs.